{
  "****************************************COMENTARIO*****************************************": "CLAVES USADAS EN LA NUEVA VERSIÓN",
  "": "",
  "app_title": "HepApp",
  "home": "Home",
  "chapters": "Secciones",
  "podcasts": "Podcasts",
  "cards": "Tarjetas",
  "figures": "Imágenes",
  "calculators": "Calculadoras",
  "resources": "Recursos",
  "pub_med": "PubMed",
  "information": "Información",
  "module_1": "Módulo 1",
  "module_2": "Módulo 2",
  "module_3": "Módulo 3",
  "references": "Referencias",
  "podcasts_1": "Podcasts 1",
  "podcasts_2": "Podcasts 2",
  "podcasts_3": "Podcasts 3",
  "podcast_1": "Podcast 1",
  "podcast_2": "Podcast 2",
  "podcast_3": "Podcast 3",
  "podcast_4": "Podcast 4",
  "podcast_5": "Podcast 5",
  "podcast_6": "Podcast 6",
  "podcast_7": "Podcast 7",
  "podcast_8": "Podcast 8",
  "podcast_9": "Podcast 9",
  "podcast_10": "Podcast 10",
  "podcast_11": "Podcast 11",
  "podcast_12": "Podcast 12",
  "podcast_13": "Podcast 13",
  "podcast_14": "Podcast 14",
  "podcast_15": "Podcast 15",
  "podcast_16": "Podcast 16",
  "podcast_17": "Podcast 17",
  "podcast_18": "Podcast 18",
  "podcast_19": "Podcast 19",
  "podcast_20": "Podcast 20",
  "podcast_21": "Podcast 21",
  "chapter_1": "Capítulo 1",
  "chapter_2": "Capítulo 2",
  "chapter_3": "Capítulo 3",
  "chapter_4": "Capítulo 4",
  "chapter_5": "Capítulo 5",
  "chapter_6": "Capítulo 6",
  "chapter_7": "Capítulo 7",
  "chapter_8": "Capítulo 8",
  "chapter_9": "Capítulo 9",
  "chapter_10": "Capítulo 10",
  "chapter_11": "Capítulo 11",
  "chapter_12": "Capítulo 12",
  "chapter_13": "Capítulo 13",
  "chapter_14": "Capítulo 14",
  "chapter_15": "Capítulo 15",
  "module_1_chapter_1": "Módulo 1 - Capítulo 1",
  "module_1_chapter_2": "Módulo 1 - Capítulo 2",
  "module_1_chapter_3": "Módulo 1 - Capítulo 3",
  "module_2_chapter_4": "Módulo 2 - Capítulo 4",
  "module_2_chapter_5": "Módulo 2 - Capítulo 5",
  "module_2_chapter_6": "Módulo 2 - Capítulo 6",
  "module_2_chapter_7": "Módulo 2 - Capítulo 7",
  "module_2_chapter_8": "Módulo 2 - Capítulo 8",
  "module_2_chapter_9": "Módulo 2 - Capítulo 9",
  "module_3_chapter_10": "Módulo 3 - Cap. 10",
  "module_3_chapter_11": "Módulo 3 - Cap. 11",
  "module_3_chapter_12": "Módulo 3 - Cap. 12",
  "module_3_chapter_13": "Módulo 3 - Cap. 13",
  "module_3_chapter_14": "Módulo 3 - Cap. 14",
  "module_3_chapter_15": "Módulo 3 - Cap. 15",
  "toc_1": "Tabla de Contenidos 1",
  "toc_2": "Tabla de Contenidos 2",
  "toc_3": "Tabla de Contenidos 3",
  "toc_4": "Tabla de Contenidos 4",
  "schemes": "Esquemas",
  "scheme_1": "Esquema 1 - Ictericia",
  "scheme_2": "Esquema 2 - Pruebas hepáticas \nanormales",
  "scheme_3": "Esquema 3 - Hepatomegalia",
  "scheme_4": "Esquema 4 - Esplenomegalia",
  "scheme_5": "Esquema 5 - Masa hepática",
  "scheme_6": "Esquema 6 - Sangrado gastrointestinal \nalto",
  "scheme_7": "Esquema 7 - Distensión Abdominal",
  "scheme_8": "Esquema 8 - Nivel de conciencia \ndisminuido",
  "map_1": "Mapa 1 - HAV",
  "map_2": "Mapa 2 - HBV",
  "map_3": "Mapa 3 - HCV",
  "map_4": "Mapa 4 - HDV",
  "map_5": "Mapa 5 - HEV",
  "map_6": "Mapa 6 - Alcohol",
  "map_7": "Mapa 7 - Obesidad",
  "normal_histology": "Histología normal",
  "cirrhosis": "Cirrosis",
  "pbc": "PBC",
  "psc": "PSC",
  "cholestasis": "Colestasis",
  "granuloma": "Granuloma",
  "hemochromatosis": "Hemocromatosis",
  "a1at_def": "A1AT def",
  "autoimmune_hepatitis": "Hepatitis Autoimmune",
  "interactive_1": "Anatomía y anatomía superficial",
  "interactive_2": "Circulación portal e hipertensión portal",
  "interactive_3": "Histología hepática y acino versus lóbulo",
  "interactive_4": "Metabolismo de la bilirrubina e ictericia por obstrucción",
  "interactive_5": "Excreción normal de cobre y enfermedad de Wilson",
  "interactive_6": "Normal y con alcohol crónico",
  "interactive_7": "Patogénesis de la ascitis y tratamiento",
  "interactive_8": "Explante y trasplante",
  "anatomy": "Anatomía",
  "surface_anatomy": "Anatomía superficial",
  "portal_circulation": "Circulación portal",
  "portal_hypertension": "Hipertensión portal",
  "liver_histology": "Histología hepática",
  "acinus_lobule": "Acino vs Lóbulo",
  "bilirubin_metabolysm": "Metabolismo de la bilirrubina",
  "obstruction_jaundice": "Ictericia por obstrucción",
  "normal_copper_excretion": "Excreción normal de cobre",
  "wildon_disease": "Enfermedad de Wilson",
  "normal": "Normal",
  "chronic_alcohol": "Alcohol crónico",
  "ascites_pathogenesis": "Patogénesis de la ascitis",
  "treatment": "Tratamiento",
  "explant": "Explante",
  "transplant": "Trasplante",
  "anterior_view_liver": "Vista anterior del hígado",
  "posterior_view_liver": "Vista posterior del hígado",
  "liver_stomach_pancreas_gall_bladder": "Hígado, estómago, pancreas y vesícula biliar",
  "liver_vasculature": "Vasculatura hepática",
  "liver_cell": "Célula hepática",
  "casl": "Pautas CASL",
  "aasld": "Pautas AASLD",
  "easl": "Pautas EASL",
  "acg": "Pautas ACG",
  "aga": "Pautas AGA",
  "ilca": "Pautas ILCA",
  "lindsay": "Atlas Lindsay",
  "back": "Atrás",
  "table_contents": "Tablas de Contenido",
  "maps": "Mapas",
  "pathology": "Patología",
  "pathology_1": "Patología 1",
  "pathology_2": "Patología 2",
  "interactive_figures": "Imágenes interactivas",
  "chapter_figures": "Imágenes de \n las secciones",
  "drawing": "Dibujo",
  "all_algorithms": "Todos los algoritmos",
  "child_pugh_score": "Índice de Child Pugh",
  "child_pugh_score_oneline": "Índice de Child Pugh",
  "meld": "MELD",
  "meld_na": "MELDNa",
  "5v_meld": "5vMELD",
  "okuda_staging_system": "Sistema Okuda",
  "clip_staging_system": "Sistema CLIP",
  "undo": "Deshacer",
  "clear_image": "Borrar imagen",
  "previous_image": "Imagen anterior",
  "next_image": "Imagen siguiente",
  "change_draw_color": "Cambiar color del pincel",
  "all_calc_diagnostic": "Todos los algoritmos - Diagnóstico",
  "encephalopaty": "Encefalopatía",
  "tumour_extent": "Extensión del tumor %",
  "ascites": "Ascitis",
  "bilirubin": "Bilirrubina",
  "inr": "INR (Ratio de normalización Internacional)",
  "albumin": "Albúmina",
  "none_masc": "Ninguno",
  "none_fem": "Ninguna",
  "controlled": "Controlada",
  "creatinine": "Creatinina",
  "diagnostic_imaging": "Diagnóstico por imagen",
  "diagnostic": "Diagnóstico",

  "Refractory": "Refractaria",
  "<=50%": "<= 50%",
  ">50%": "> 50%",
  "grade_1_2": "Grado 1 - 2",
  "grade_3_4": "Grado 3 - 4",
  "calculate_cp_score": "Calcular CPS",
  "calculate_meld": "Calcular MELD",
  "calculate_okuda": "Calcular Okuda",
  "calculate_clip": "Calcular CLIP",
  "tumour_number": "Número de tumores",
  "okuda": "Okuda",


  "enter_text": "Introduzca texto",
  "save_settings": "Guardar ajustes",
  "international_units": "Unidades Internacionales",
  "yes": "Sí",
  "no": "No",
  "jaundice": "Ictericia",
  "abn_liver_tests": "Pruebas hepáticas anormales",
  "hepatomegaly": "Hepatomegalia",
  "splenomegaly": "Esplenomegalia",
  "liver_mass": "Masa hepática",
  "ugi_bleed": "Sangrado gastrointestinal alto",
  "abdominal_distention": "Distensión Abdominal",
  "decreased_loc": "Nivel de conciencia disminuido",
  "previous": "Valores anteriores",
  "close": "Cerrar",
  "encephalopathy": "Encefalopatía",
  "more_information": "Más información",
  "previous_values": "Valores anteriores",
  "on": "ON",
  "off": "OFF",
  "cancel": "Cancelar",
  "accept": "Aceptar",
  "fill_empty_fields": "Por favor, rellena los campos vacíos",
  "pvt_complete": "PVT (Trombosis de la Vena Porta)",
  "error": "Error",
  "calculators_clip": "Calculadoras - CLIP",
  "calculators_meld": "Calculadoras - MELD",
  "calculators_okuda": "Calculadoras - Okuda",
  "calculators_child_pugh_score": "Calculadoras - Child Pugh Score",
  "afp": "AFP",
  "clip": "CLIP",
  "A": "A",
  "B": "B",
  "C": "C",
  "0": "0",
  "1": "1",
  "2": "2",
  "3": "3",
  "4": "4",
  "5": "5",
  "6+": "6+",
  "calculators_all_algorithms_diagnostic": "Calculadoras - Todos los algoritmos - Diagnóstico",
  "calculators_all_algorithms_laboratory": "Calculadoras - Todos los algoritmos - Laboratorio",
  "calculators_all_algorithms_clinical": "Calculadoras - Todos los algoritmos - Clínico",
  "calculators_all_algorithms_results": "Calculadoras - Todos los algoritmos - Resultados",
  "calculators_all_algorithms_summary": "Calculadoras - Todos los algoritmos - Resumen",
  "calculators_all_algorithms_alberta": "Calculadoras - Todos los algoritmos - Alberta",
  "laboratory_values": "Valores de laboratorio",
  "clinical_questions": "Cuestiones clínicas",
  "results": "Resultados",
  "tumour_size": "Tamaño del tumor (Diám. cm)",
  "pvi_portal_vein_invasion": "PVI (Invasión de la vena porta)",
  "nodes": "Nodos",
  "metastasis": "Metástasis",
  "portal_hypertension_complete": "Hipertensión portal (varices y/o esplenomegalia)",
  "next": "Siguiente >",
  "summary_values": "Resumen de valores",
  "platelets": "Plaquetas",
  "alp": "ALP",
  "alp_upper_limit": "ALP (Límite superior de lo normal)",
  "alp_limit": "ALP (Límite superior)",
  "-": "-",
  "ast": "AST",
  "ast_upper_limit": "AST (Límite superior de lo normal)",
  "ast_limit": "AST (Límite superior)",
  "settings": "Preferencias",
  "age_cutoff": "Límite de edad",
  "lt_criteria": "Criterio de trasplante",
  "milan_criteria": "Milán",
  "ttv_afp": "TTV + AFP",
  "ucfs": "UCFS",
  "up_to_seven": "Up to Seven",

  "ecog": "ECOG",
  "apri": "APRI",
  "getch": "GETCH",
  "tnm": "TNM",
  "cupi": "Cupi",
  "bclc": "BCLC",
  "liver_function": "Función hepática",
  "staging_algorithms": "Algoritmos de estadificación",
  "alberta_hcc_algorithm": "Algoritmo Alberta HCC",
  "recommended_treatment": "Tratamiento recomendado:",
  "tumours": "Tumores",
  "#1": "#1",
  "#2": "#2",
  "#3": "#3",
  "#4": "#4",
  "#5": "#5",
  "#6": "#6",
  "pvi": "PVI",
  "pvt": "PVT",
  "preclude_major_surgery": "Excluir cirugía mayor",
  "age": "Edad",
  "inr_summary": "INR",
  "value_summary": "Resumen de valores",
  "Vodcast 01 - Introduction": "Vodcast 01 - Introducción",
  "Vodcast 02 - Anatomy": "Vodcast 02 - Anatomía",
  "Vodcast 03 - Cell Biology": "Vodcast 03 - Biología de la célula",
  "Vodcast 04 - History": "Vodcast 04 - Historia",
  "Vodcast 05 - Physical Exam": "Vodcast 05 - Examen físico",
  "Vodcast 06 - Investigations": "Vodcast 06 - Investigaciones",
  "Vodcast 07 - Pathology": "Vodcast 07 - Patología",
  "Vodcast 08 - Extrahepatic Cholestasis": "Vodcast 08 - Colestasis extrahepática",
  "Vodcast 09 - Intrahepatic Cholestasis": "Vodcast 09 - Colestasis extrahepática",
  "Vodcast 10 - ABCs of Viral Hepatitis": "Vodcast 10 - ABCs de la hepatitis viral",
  "Vodcast 11 - HBV and HCV": "Vodcast 11 - HBV y HCV",
  "Vodcast 12 - Alcohol and NAFLD": "Vodcast 12 - Alcohol y NAFLD",
  "Vodcast 13 - Genetic Liver Diseases": "Vodcast 13 - Enfermedades genéticas del hígado",
  "Vodcast 14 - AIH and DILI": "Vodcast 14 - AIH y DILI",
  "Vodcast 15 - ALF": "Vodcast 15 - ALF",
  "Vodcast 16 - Hepatosplenomegaly and Liver Masses": "Vodcast 16 - Hepatoesplenomegalia y masas en el hígado",
  "Vodcast 17 - Liver Cancer": "Vodcast 17 - Cáncer de hígado",
  "Vodcast 18 - Varices": "Vodcast 18 - Varices",
  "Vodcast 19 - Ascites": "Vodcast 19 - Ascitis",
  "Vodcast 20 - Encephalopathy and Other Complications": "Vodcast 20 - Encefalopathía y otras complicaciones",
  "Vodcast 21 - Liver Transplant": "Vodcast 21 - Trasplante de hígado",
  "vodcasts": "Vodcasts",
  "meld_info_title": "Información MELD",
  "meld_info_content": "Límite inferior de 1.0 para INR. \nLímite inferior de 1.0 mg/dL (17.1 umol/L) para Bilirrubina. \nCreatinina limitada entre 1.0 mg/dL (88.4 umol/L) y 4.0 mg/dL (353.6 umol/L). \nSodio limitado entre 125 mmol/L (54.38 mg/dL) y 140 mmol/L (60.90 mg/dL). \nAlbúmina limitada entre 1 g/dL (10g/L) y 4 g/dL (40 g/L).",
  "stage_0_very_early": "STAGE 0\nVery Early",
  "stage_a_early": "STAGE A\nEarly",
  "stage_b_intermediate": "STAGE B\nIntermediate",
  "stage_c_advanced": "STAGE C\nAdvanced",
  "stage_d_end_stage": "STAGE D\nEnd Stage",
  "tumour": "Tumor",
  "child_pugh_class": "Child Pugh Class",
  "prognosis": "Pronóstico",
  "1_(≤2cm)": "1(<=2cm)",
  "1_(≥2cm)_or_up_to_3_(≤3cm)": "1 (≥2cm) o hasta 3 (≤3cm)",
  ">_milan_criteria": "> Milan Criteria",
  "pvi_n1_m1": "PVI, N1, M1",
  "b8_9_c": "B8-9/C",
  "a_b7": "A/B7",
  "a*": "A*",
  "a": "A",
  "b": "B",
  "c": "C",
  "b_c": "B/C",
  "portal_ht_and_or_bilirubin": "Hipertensión Portal y/o\nbilirrubina ↑",
  "lt_candidate?": "¿Candidato a\n trasplante?",
  "lt_long": "Trasplante de hígado",
  "ecog_ps": "¿ECOG PS?",
  "0_1": "0-1",
  ">2": ">2",
  "main_pvt?": "Main PVT?",
  "0_2": "0-2",
  "resection": "Resección",
  "rfa": "RFA",
  "lt": "LT",
  "curative_options": "Opciones curativas",
  "5_year_survival": "Supervivencia en 5 años ~ 50-70%",
  "tare": "TARE",
  "tace": "TACE",
  "sorafenib": "Sorafenib",
  "palliative_options": "Opciones Paliativas",
  "~20_mo": "~ 20 meses",
  "~11_mo": "~ 11 messe",
  "best_supportive_care": "Cuidados\nPaliativos",
  "~3_mo": "~ 3 meses",
  "very_early_0": "Estadio 0: Muy temprano",
  "early_a": "Estadio A: Temprano",
  "intermediate_b": "Estadio B: Intermedio",
  "advanced_c": "Estadio C: Avanzado",
  "end_stage_d": "Estadio D: Etapa final",
  "calculator": "Calculadora",
  "patient_requirements": "Patient requirements: ",
  "best_patreq_0": "• Poor performance status (ECOG > 2).",
  "best_patreq_1": "• Decompensated liver function (Child-Pugh class C).",
  "goals": "Goals: ",
  "best_goal_0": "• To mantain or to improve the patient's quality of life (to control tumor-related symptoms).",
  "recommendation": "Recommendation:",
  "best_recomm_0": "• Best Supportive Care",
  "best_recomm_1": "• Palliative chemotherapy may adversely affect outcome",
  "terminal_stage_hepatocellular_carcinoma": "Terminal Stage Hepatocellular Carcinoma: ",
  "intermediate_stage_hepatocellular_carcinoma": "Intermediate Stage Hepatocellular Carcinoma: ",
  "definitions_goals_recommendations": "Definitions, Goals, and Recommendation",
  "terminal_stage_best_supportive_care": "Terminal Stage: \nBest Supportive\nCare",
  "intermediate_stage_tace": "Intermediate\nStage:\nTACE",
  "tumor_requirements": "Tumor requirements:",
  "transarterial_chemo_embolization": "Transarterial Chemo-Embolization (TACE):",
  "tace_patreq_0": "• Good performance status (ECOG 0-1).",
  "tace_patreq_1": "• Well-compensated liver function (Chil-Pugh class A) and only select patients with impaired liver function (Child-Pugh B 7).",
  "tace_tumreq_0": "• Multinodular disease.",
  "tace_tumreq_1": "• Absence of extra-hepatic disease.",
  "tace_tumreq_2": "• Patency of the main portal vein (as assessed by ultrasound Dopller or MR angiography) for TACE.",
  "tace_tumreq_3": "• Adequate renal function.",
  "tace_goal_0": "• To mantain or to improve the patient's quality of life (to control or to delay the onset of tumor-related symptoms, possibly while awaiting transplant).",
  "tace_goal_1": "• To prolong life, if possible.",
  "tace_recomm_0": "• Transarterial chemo-embolization or transarterial radioembolization.",
  "tace_desc_0": "• Blood supply to hepatocellular carcinomas is preferentially derived from the hepatic artery rather than the portal vein. ",
  "tace_desc_1": "• Involves placement of an intravascular catheter into the hepatic artery (inserted percutaneously in the femoral artery and advanced through the abdominal aorta and celiac trunk). Injection of chemotherapy (with or without the oily contrast agent, Lipiodol) followed by embolic agents (e.g.: gelatin-sponge particles, Embosphere®) occludes the relevant branch of the hepatic artery and localizes the chemotherapy. ",
  "tace_desc_2": "Meta-analyses of randomized controlled trials demonstrate a survival benefit of TACE.33,34 Drug-eluting beads (DEBs) decrease the systemic exposure to doxorubicin.35 Although DEBs have not been shown to be superior to conventional TACE, they offer a more standardized technique and are better tolerated with fewer complications.27 Recent cohort studies are demonstrating median survival of 4 years after TACE with DEBs in carefully selected patients.28 ",
  "tace_desc_3": "• If Doxorubicin is considered, assess the left ventricular ejection fraction with a MUGA scan or echocardiogram prior to the procedure. It is not clear if MUGA or ECHO is still required before TACE with DEBs. ",
  "advanced_stage_sbrt": "Advanced Stage:\nSBRT",
  "advanced_stage_hepatocellular_carcinoma": "Advanced Stage Hepatocellular Carcinoma: ",
  "stereotactic_body_radiotherapy": "Stereotactic Body RadioTherapy (SBRT):",
  "sbrt_patreq_0": "• Good performance status (ECOG 0, 1, or 2).",
  "sbrt_patreq_1": "• Well-compensated liver function (Child-Pugh class A).",
  "sbrt_tumreq_0": "• Disease ineligible for, or that progressed after, surgical or locoregional therapy.",
  "sbrt_goal_0": "• To maintain or to improve the patient's quality of life (to control or to delay the onset of tumor-related symptoms).",
  "sbrt_goal_1": "• To prolong life, if possible.",
  "sbrt_recomm_0": "• First-line treatment: Sorafenib or participation in a clinical trial, if available.",
  "sbrt_recomm_1": "• Second-line treatment: participation in a clinical trial, if available.",
  "sbrt_desc_0": "• There is growing experience with providing ionizing radiotherapy to HCC using very conformal dose distribution, with image guidance and motion management to provide high doses of radiation to the HCC while minimizing exposure to the adjacent liver or other tissues.",
  "sbrt_desc_1": "• SBRT can provide good local control of HCC range (ranging from 43% to 100% at 1 year) which can depend on factors such as lesion size and number, and the delivered radiation dose. It has been used in patients with portal vein invasion and to bridge patients to liver transplantation.",
  "sbrt_desc_2": "• Patients should be discussed at multidisciplinary rounds. SBRT can be considered when alternative therapies such as ablation/embolization techniques have failed or are contraindicated.",
  "sbrt_desc_3": "• Patients can experience worsening of liver function with SBRT and tolerance to normal liver is the main dose limiting constraint. Most safety evidence is for patients with Child-Pugh A disease. Evidence is more limited for Child-Pugh B disease and in practice treatment dose is lowered to reduce the chance of treatment toxicities. Treatment of patients with Child-Pugh C disease is not recommended as the safety of liver SBRT in this population has not been determined.",
  "sbrt_desc_4": "• Continued clinical trials in the use of liver SBRT are recommended. Studies evaluating SBRT in combination with sorafenib are currently underway. Enrollment of patients into clinical trials or investigational protocols should be encouraged.",
  "early_stage_rfa": "Early Stage:\nRFA",
  "early_stage_hepatocellular_carcinoma": "Early Stage HepatoCellular Carcinoma: ",
  "radiofrequency_ablation_or_precutaneous": "Radiofrequency Ablation (RFA) or Percutaneous Ethanol Injection (PEI):",
  "rfa_patreq_0": "• Good performance status (ECOG 0).",
  "rfa_patreq_1": "• Well-compensated liver function (Child-Pugh class A).",
  "rfa_tumreq_0": "• Solitary tumor confined to one lobe of liver or three nodules (all 3 cm).",
  "rfa_tumreq_1": "• Absence of vascular invasion and extra-hepatic disease.",
  "rfa_tumreq_2": "• Complete removal of the tumor(s) with a margin of 1 cm anticipated.",
  "rfa_goal_0": "• To render patient free of disease and to delay or prevent recurrence.",
  "rfa_recomm_0": "• Resection, liver transplantation, or ablation.",
  "rfa_desc_0": "• Provides tumor control pending transplantation or as an adjunct or alternative to resection.",
  "rfa_desc_1": "• Recent series of radiofrequency ablation report local recurrence rates under 5% and five-year survivals equal to resection. Radiofrequency ablation requires fewer sessions to ablate tumors and results in improved survival when compared to percutaneous ethanol injection.",
  "rfa_desc_2": "• Survival rates with radiofrequency ablation may be similar to surgical resection; however, two-year recurrence rates are higher following percutaneous ethanol injection and radiofrequency ablation than with resection.",
  "rfa_desc_3": "• Best outcomes are achieved from radiofrequency ablation when tumors are centrally located, measure under 3 cm, and are distant from \"heat sinks\" (blood vessels). Consider percutaneous ethanol injection or transarterial chemo-embolization (TACE) when tumors are in a subcapsular location, exceed 4 cm, or are located adjacent to blood vessels.",
  "rfa_desc_4": "• Hepatocellular carcinomas are considered \"treated\" only if the imaging study demonstrates complete tumor necrosis (without contrast enhancement to suggest residual disease).",
  "intermediate_stage_tare": "Intermediate Stage:\nTARE",
  "transarterial_radioembolization": "Transarterial Radioembolization (TARE):",
  "tare_patreq_0": "• Good performance status (ECOG 0-1).",
  "tare_patreq_1": "• Well-compensated liver function (Child-Pugh class A) and only select patients with impaired liver function (Child-Pugh B 7).",
  "tare_tumreq_0": "• Multinodular disease.",
  "tare_tumreq_1": "• Absence of extra-hepatic disease.",
  "tare_tumreq_2": "• Patency of the main portal vein (as assessed by ultrasound Doppler or MR angiography) for TACE.",
  "tare_tumreq_3": "• Adequate renal function.",
  "tare_goal_0": "• To maintain or to improve the patient's quality of life (to control or to delay the onset of tumor-related symptoms, possibly while awaiting transplant).",
  "tare_goal_1": "• To prolong life, if possible.",
  "tare_recomm_0": "• Transarterial chemo-embolization or transarterial radioembolization.",
  "tare_desc_0": "• TARE or selective internal radiotherapy (SIRT) uses microsphere loaded with yttrium-90 (Y) to deliver radiation directly into the tumour via the hepatic artery. Unlikely TACE it is done as an outpatient. Prior to the TARE, the patient requires a staging angiogram to calculate the liver-to¬lung shunt fraction in Nuclear Medicine using technicium-99 macro-aggregated albumin (Tc MAA). At the same time selective embolization of the gastroduodenal arteries is carried out to prevent delivery of radiation to the stomach and duodenum. The procedure may be repeated depending upon response.",
  "tare_desc_1": "• There are no direct comparisons of TARE with TACE. However, large cohort studies from Europe and the USA have shown similar survival to TACE in BCLC stage B patients.",
  "tare_desc_2": "• TARE, unlike TACE, can be performed safely in patients with portal vein thrombosis, as the microspheres used in TARE are smaller and less embolic.",
  "tare_desc_3": "• TARE may be considered for patients who have progressive disease after TACE, who cannot tolerate doxorubicin or who are likely to fail TACE (large HCC).",
  "tare_desc_4": "• TARE may also be more effective than TACE in bridging or down-staging patients to liver transplantation.",
  "tare_desc_5": "• Outcomes following TARE are best in patients with preserved liver function (Child-Pugh score <8 or MELD score <13). Patients should be selected for TARE at MDT meetings.",
  "tare_desc_6": "• As there remains uncertainty about TARE efficacy compared to TACE (intermediate stage) or sorafenib (advanced stage), clinical trials are encouraged.",
  "advanced_stage_sorafenib": "Advanced Stage:\nSorafenib",
  "sorafenib_patreq_0": "• Good performance status (ECOG 0, 1, or 2).",
  "sorafenib_patreq_1": "• Well-compensated liver function (Child-Pugh class A).",
  "sorafenib_tumreq_0": "• Disease ineligible for, or that progressed after, surgical or locoregional therapy.",
  "sorafenib_goal_0": "• To maintain or to improve the patient's quality of life (to control or to delay the onset of tumor-related symptoms).",
  "sorafenib_goal_1": "• To prolong life, if possible.",
  "sorafenib_recomm_0": "• First-line treatment: Sorafenib or participation in a clinical trial, if available.",
  "sorafenib_recomm_1": "• Second-line treatment: participation in a clinical trial, if available.",
  "sorafenib_400_mg": "Sorafenib 400 mg po BID:",
  "sorafenib_desc_0": "• Represents an orally active inhibitor of multiple cell surface tyrosine kinases (e.g.: VEGFR, PDGFR-15, c-kit, FLT3, RET) as well as downstream intracellular kinases (e.g.: Rat) involved in angiogenesis and tumor progression.",
  "sorafenib_desc_1": "• Delays progression and improves overall survival when compared to placebo in two randomized, double blind, placebo-controlled, phase Ill trials:",
  "sorafenib_desc_2": "• Hypothyroidism develops in 18% of patients within two to four months of starting Sorafenib. Obtain a baseline TSH and then monitor levels every six weeks.",
  "sorafenib_desc_3": "• Increases the incidence of arterial thromboembolic events (1.4%, RR 3.03, p = 0.015).",


  "******************************************COMENTARIO**************2": "CLAVES ANTIGUAS PARA BORRAR",
  "AFP": "AFP",
  "ageCutoff": "Límite de edad",
  "ageCutoffResumen": "Edad",
  "algoritmoAlbertaHCC": "Algoritmo Alberta HCC",
  "APRIresultado": "APRI:",
  "avisoErrorObtenerVersionRecursoRemoto": "Error al obtener la versión del recurso remoto. Reintente la operación de nuevo.",
  "barraLateralAbrir": "abrir",
  "barraLateralCerrar": "cerrar",
  "BCLCresultado": "BCLC:",
  "cirrosis": "Cirrosis",
  "cirrosisResult": "Cirrosis:",
  "CLIPresultado": "Clip:",
  "contacts": "Contacto y agradecimientos",
  "CPSresult": "Índice Child Pugh:",
  "cpsresult": "Índice Child Pugh:",
  "criterioMilan": "Criterio Milan",
  "criterioUpToSeven": "Up to Seven",
  "cuestionesClinicas": "Cuestiones clínicas",
  "CupiResult": "Cupi:",
  "diagnosticImaging": "Diagnóstico por imagen",
  "dialysis": "¿Diálisis?",
  "dialysisResumen": "Diálisis",
  "errorConexionFicheroRemoto": "No se puede conectar con el recurso remoto. Compruebe su conexión a Internet e inténtelo de nuevo. Si el problema persiste el recurso podría no estar disponible.",
  "errorDescarga": "La descarga no se ha completado, revise su conexión a Internet e inténtelo de nuevo.",
  "errorDescargaPrerrequisitos": "En este momento no se cuentan con los requisitos necesarios para solicitar la descarga (ya hay demasiadas descargas en marcha). Inténtelo de nuevo más adelante.",
  "errorElementosLista": "No hay ningún elemento que mostrar en la lista.",
  "errorFaltanPermisosEscritura": "Se necesitan permisos de escritura antes de continuar. Intente la operación de nuevo más adelante.",
  "errorRecursoRegistradoLocalNoExiste": "El recurso ya descargado que HepApp intenta visualizar ha sido borrado manualmente o por otra tercera aplicación, o el almacenamiento externo no se encuentra disponible.",
  "errorSincronizarBaseDatos": "No se ha sincronizado el contenido de la aplicación con el servidor.",
  "exitoSincronizarBaseDatos": "El contenido de la aplicación se ha sincronizado correctamente con el servidor.",
  "grade1_2": "Grado 1-2",
  "grade3_4": "Grado 3-4",
  "mensajeErrorValidacionCamposAjustesCalculadora": "Algún campo requerido en los <![CDATA[<b><i>ajustes</i></b>]]> se encuentra vacío o tiene un formato no válido.",
  "mensajeErrorValidacionCamposFormatoCalculadora": "Alguno de los campos tiene un formato erróneo.",
  "mensajeErrorValidacionCamposVaciosCalculadora": "Alguno de los campos requeridos está vacío",
  "moduleChapters": "Módulo capítulos",
  "modulePodcasts": "Módulo podcasts",
  "moduloSinRecursosSeccionSeleccionada": "El módulo seleccionado no tiene recursos para esa sección.",
  "notificaErrorDesarrollador": "Se ha producido un error inesperado, por favor contacta con el desarrollador.",
  "numberOfTumours": "Número de tumores",
  "numberOfTumoursResumen": "Tumores",
  "obteniendoVersionRecursoRemoto": "Se están obteniendo datos necesarios previos a iniciar la descarga. Inténtelo de nuevo más adelante.",
  "ok": "OK",
  "portalHipertension": "Hipertensión portal (varices y/o esplenomegalia)",
  "portalHipertensionResumen": "Hipertensión portal",
  "portalPrincipalTrombosis": "PVT (Trombosis de la Vena Porta)",
  "portalVeinInvasion": "PVI (Invasión de la vena porta)",
  "portalVeinInvasionResumen": "PVI",
  "precludeMajorSurgery": "Precluir cirugía mayor",
  "refractory": "Refractario",
  "reintentandoObtencionVersionRecursoRemoto": "Reintentando la obtención de la versión del recurso remoto…",
  "reset_values": "Restablecer valores",
  "resumenDeValores": "Resumen de valores",
  "sincronizandoContenidoAplicacion": "Sincronizando el contenido de\nla aplicación con el servidor…",
  "sodium": "Sodio",
  "textoAnimacionAperturaConexion": "Cargando el recurso remoto, espere por favor.",
  "textoAnimacionDescarga": "Descarga en curso: Por favor, espera\na que se complete.",
  "textoErrorCapturaPantalla": "Se ha producido un error al guardar la captura de pantalla.",
  "textoExitoCapturaPantalla": "Se ha guardado la captura de pantalla con éxito.",
  "tipComenzarSolicitandoDescargaRecurso": "Para comenzar, solicita la descarga del\nrecurso usando el control descargar de la\nbarra de herramientas inferior.",
  "tituloCalculadoraCLIP": "CLIP",
  "tituloCalculadoraFull": "Todos los \nalgoritmos",
  "tituloCalculadoraOKUDA": "Okuda",
  "tituloDescargaRecurso": "HepApp: Descarga del recurso",
  "tituloDialogoSeleccionarColor": "Selecciona un color",
  "tituloErrorRecurso": "Recurso - ERROR.",
  "tituloErrorValidacionCalculadora": "Error de validación",
  "tituloImagenesTablaContenidos": "Tabla de Contenidos",
  "tituloLieverFunction": "FUNCIÓN HEPÁTICA",
  "tituloPantallaAlberta": "Alberta",
  "tituloPantallaCuestionesClinicas": "Clínico",
  "tituloPantallaDiagnostico": "Diagnóstico",
  "tituloPantallaResultados": "Resultados",
  "tituloPantallaResumenResultados": "Resumen",
  "tituloPantallaValoresLaboratorio": "Laboratorio",
  "tituloStagingAlgorithms": "ALGORITMOS ESTADÍSTICOS",
  "TNMresultado": "TNM:",
  "tratamientoRecomendado": "Tratamiento recomendado",
  "TTVmasAFP": "TTV+AFP",
  "tumourExtent": "Extensión del tumor %",
  "tumourExtentResumen": "Extensión del tumor",
  "tumoursSize": "Tamaño del tumor (DIAM. cm)",
  "txtLTcriteria": "Criterio LT",
  "valoresLaboratorio": "Valores de laboratorio",
  "valorEntradaFueraRango": "Algún parámetro tiene un valor fuera del rango válido",
  "varices": "Varices",
  "x10E3ul": "x10E3/uL",
  "x10E9l": "x10E9/L"
}
